Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists
Warren T. Yacawych, Yi Wang, Guoxiang Zhou, Shad Hassan, Cagri Bodur, Elisabeth Walters, John G. Santinga, Frederike Sass, Martin deVaux, Stace Kernodle, Iris Wu, Jenny M. Brown, Dylan Belmont-Rausch, Alan C. Rupp, Abigail J. Tomlinson, Zitian Lin, Emma VanTongeren, Anna Secher, Kirsten Raun, Tune H. Pers, Randy J. Seeley, Martin G. Myers Jr., Weiwei Qiu
Warren T. Yacawych, Yi Wang, Guoxiang Zhou, Shad Hassan, Cagri Bodur, Elisabeth Walters, John G. Santinga, Frederike Sass, Martin deVaux, Stace Kernodle, Iris Wu, Jenny M. Brown, Dylan Belmont-Rausch, Alan C. Rupp, Abigail J. Tomlinson, Zitian Lin, Emma VanTongeren, Anna Secher, Kirsten Raun, Tune H. Pers, Randy J. Seeley, Martin G. Myers Jr., Weiwei Qiu
View: Text | PDF
Research Article Metabolism Neuroscience

A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists

  • Text
  • PDF
Abstract

Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP1RAs) effectively reduce feeding to treat obesity, although nausea and other aversive side effects of these drugs can limit their use. Brainstem circuits that promote satiation and mediate the physiological control of body weight can be distinguished from those that cause aversion. It remains unclear, however, whether brainstem Glp1r neurons contribute to the normal regulation of energy balance and whether GLP1RAs control appetite via circuits distinct from those that mediate aversive responses. Here, we silenced Glp1r neurons in the nucleus of the solitary tract (NTS) or area postrema (AP) (NTSGlp1r or APGlp1r neurons, respectively) or restored their GLP1R signaling on an otherwise GLP1R-deficient background to determine physiological and pharmacological roles for each neuron population. Although NTSGlp1r neurons contributed to the normal restraint of food intake and body weight, they failed to mediate GLP1RA-dependent weight loss. In contrast, while we detected no role for APGlp1r neurons in physiological feeding, they mediated both the weight-lowering and aversive effects of GLP1RAs. Therefore, while nonaversive NTSGlp1r neurons controlled physiologic satiation they did not contribute to weight loss during GLP1RA treatment. Rather, APGlp1r neurons mediated both the weight-lowering and aversive effects of GLP1RAs, preventing the separation of their nauseating and weight-loss effects at a circuit level.

Authors

Warren T. Yacawych, Yi Wang, Guoxiang Zhou, Shad Hassan, Cagri Bodur, Elisabeth Walters, John G. Santinga, Frederike Sass, Martin deVaux, Stace Kernodle, Iris Wu, Jenny M. Brown, Dylan Belmont-Rausch, Alan C. Rupp, Abigail J. Tomlinson, Zitian Lin, Emma VanTongeren, Anna Secher, Kirsten Raun, Tune H. Pers, Randy J. Seeley, Martin G. Myers Jr., Weiwei Qiu

×

Figure 3

Lira reduces food intake and body weight of APGlp1r-Re but not NTSGlp1r-Re mice.

Options: View larger image (or click on image) Download as PowerPoint
Lira reduces food intake and body weight of APGlp1r-Re but not NTSGlp1r-...
The indicated strains of mice were injected with vehicle for 2 days, Lira for 5–7 days, and vehicle again for 1–2 days; food intake and body weight were measured daily. (A and B) Food intake (A) and body weight (B) were normalized to baseline for chow-fed Glp1rKO (n = 5–6), Glp1rWT (n = 6–7), NTSGlp1r-Re (n = 5), and APGlp1r-Re (n = 9–10) mice. (C and D) Daily food intake for HFD-fed mice. (C) Daily food intake was normalized to baseline for vehicle- and Lira-treated mice and (D) cumulative food intake was measured over the course of Lira treatment. Daily body weight was normalized to baseline (E) and to the total percentage of body weight change (F) during Lira treatment for HFD-fed Glp1rKO (n = 5), Glp1rWT (n = 6), NTSGlp1r-Re (n = 5), and APGlp1r-Re (n = 9) mice. Pink circles in F indicate data for female mice; brown circles indicate data for male mice. All graphs show the mean ± SEM. Repeated-measures, 2-way ANOVA with Tukey’s multiple comparisons for A–E. One-way ANOVA with Tukey’s multiple comparisons for F. A–E: Groups (indicated by the letter matching the color of the line) with different letters are statistically significant at the indicated time point, P < 0.05. F: NS = P > 0.05; **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts